• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing LivaNova (LIVN) Valuation After Recent Share Price Momentum And Perceived Intrinsic Discount

    Simply Wall St·01/09/2026 19:24:03
    Listen to the news

    LivaNova (LIVN) has drawn fresh attention after recent trading, with the stock last closing at $64.95. Investors are weighing this move against the company’s current performance metrics and recent return profile.

    See our latest analysis for LivaNova.

    The recent share price move comes on top of a 28.13% 90 day share price return and a 35.20% total shareholder return over the past year. This suggests that momentum has been building rather than fading.

    If LivaNova has caught your eye, it could be worth scanning other healthcare names too. You could start with healthcare stocks as a way to spot more ideas.

    The key question now is whether LivaNova’s recent gains still leave room for upside, given an indicated intrinsic discount of 27.16% and a price target above the current US$64.95 level, or if the market is already pricing in future growth.

    Most Popular Narrative: 6% Undervalued

    Compared to the last close of US$64.95, the most followed narrative points to a fair value of about US$69.10, implying some remaining upside based on its own assumptions.

    The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

    Read the complete narrative.

    Curious what earnings path and margin profile need to line up for that valuation to make sense? The narrative leans on steady top line progress, a turn to profitability, and a future earnings multiple that currently sits below the broader medical equipment peer group. The exact mix of growth, margins, and discount rate might surprise you.

    Result: Fair Value of $69.10 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, that story can change quickly if higher R&D spending does not translate into commercially successful devices or if tighter reimbursement and cost controls limit hospital demand.

    Find out about the key risks to this LivaNova narrative.

    Build Your Own LivaNova Narrative

    If you see the story differently, or simply want to test your own assumptions against the numbers, you can build a custom view in minutes, starting with Do it your way.

    A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding LivaNova.

    Looking for more investment ideas?

    If you are serious about building a stronger portfolio, do not stop at a single company. Use focused stock lists to spot opportunities before they feel obvious.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.